中国实用妇科与产科杂志

中国实用妇科与产科杂志

• 专题笔谈 • 上一篇    下一篇

初诊上皮性卵巢癌的一线化疗

  

  1. 北京大学人民医院妇科肿瘤中心，北京 100044
  • 出版日期:2021-06-02 发布日期:2021-07-06
  • 通讯作者: 崔恒
  • 基金资助:
    国家重点研发计划（2016YFA0201404）

First-line chemotherapy for newly diagnosed epithelial ovarian cancer.

  1. Center of Gynecologic Oncology，Peking University People's Hospital，Beijing 100044，China
  • Online:2021-06-02 Published:2021-07-06

摘要： 晚期上皮性卵巢癌的初始治疗模式为肿瘤细胞减灭术+铂类为基础的联合化疗+一线维持治疗。文章主要阐述了初诊上皮性卵巢癌一线化疗方案的演变和规范应用。紫杉醇联合卡铂3周疗方案仍然是初治上皮性卵巢癌的一线首选化疗方案，其卓越地位无法撼动。同时，文章还回顾了初始化疗中使用贝伐珠单抗的指征，以及其他一线化疗方案的选择指征。最后，文章指出了临床实践中上皮性卵巢癌化疗不规范的问题，强调应重视化疗的规范性，以助于提高我国晚期上皮性卵巢癌患者的生存率。

关键词: 上皮性卵巢癌, 一线化疗, 规范化治疗

Abstract: The initial treatments for epithelial ovarian cancer include cytoreductive surgery，platinum-based chemotherapy and maintenance therapy. In this article，we present the evolution and standardized application of first-line chemotherapy for newly diagnosed epithelial ovarian cancer. The regimen of paclitaxel followed by carboplatin every three weeks is still the preferred regimen for newly diagnosed epithelial ovarian cancer and its outstanding status has never been replaced. In this article，we also review the indications for bevacizumab and other recommended regimens for newly diagnosed epithelial ovarian cancer. At the end，we point out the problems of non-standardized chemotherapy in clinical practice and stress the importance of standard chemotherapy in order to help increase the survival rate of patients with advanced epithelial ovarian cancer.

Key words: epithelial ovarian cancer, first-line chemotherapy, standard therapy

中图分类号: